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Abstract: Ewing sarcoma (EwS) is an aggressive cancer displaying an undifferentiated small-round-cell
histomorphology that can be easily confused with a broad spectrum of differential diagnoses. Using
comparative transcriptomics and immunohistochemistry (IHC), we previously identified BCL11B and
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GLG1 as potential specific auxiliary IHC markers for EWSR1-FLI1-positive EwS. Herein, we aimed at
validating the specificity of both markers in a far larger and independent cohort of EwS (including
EWSR1-ERG-positive cases) and differential diagnoses. Furthermore, we evaluated their intra-tumoral
expression heterogeneity. Thus, we stained tissue microarrays from 133 molecularly confirmed EwS
cases and 320 samples from morphological mimics, as well as a series of patient-derived xenograft
(PDX) models for BCL11B, GLG1, and CD99, and systematically assessed the immunoreactivity
and optimal cut-offs for each marker. These analyses demonstrated that high BCL11B and/or GLG1
immunoreactivity in CD99-positive cases had a specificity of 97.5% and an accuracy of 87.4% for
diagnosing EwS solely by IHC, and that the markers were expressed by EWSR1-ERG-positive EwS.
Only little intra-tumoral heterogeneity in immunoreactivity was observed for differential diagnoses.
These results indicate that BCL11B and GLG1 may help as specific auxiliary IHC markers in diagnosing
EwS in conjunction with CD99, especially if confirmatory molecular diagnostics are not available.
Keywords: Ewing sarcoma; biomarkers; immunohistochemistry; diagnostics; BCL11B; GLG1
1. Introduction
Ewing sarcoma (EwS) is an undifferentiated small-round-cell sarcoma driven by FET-ETS fusion
oncoproteins [1]. EwS constitutes the second most common bone-associated sarcoma in children,
adolescents, and young adults after osteosarcoma [1–3]. However, EwS also occurs in soft tissue,
although less frequently and predominantly in older patients [4,5].
In more than 30% of cases, micrometastases are present at time of diagnosis [6]. For these patients,
outcome is rather poor with a long-term survival rate of around 25% [6–8], with a slightly better
survival rate for patients exhibiting exclusively lung metastases [9,10]. Nevertheless, patients with
localized (i.e., non-metastatic) disease can be effectively treated with combined chemotherapy and
surgery [11–13], resulting in a long-term survival rate of more than 70% [14–16]. Besides metastasis,
larger tumor size also correlates negatively with patients’ overall survival [8]. Although there is an
ongoing debate whether time to diagnosis is associated with metastasis and survival of individuals
affected by EwS [17,18], early and robust diagnosis of EwS is important to assign patients quickly to
the appropriate therapy and to avoid unnecessary delay in treatment.
From a morphological point of view, histopathological diagnosis of EwS has been notoriously
difficult due to its highly undifferentiated small-round-cell phenotype being shared with a variety of
differential diagnoses [19], such as neuroblastoma, rhabdomyosarcoma, lymphoblastic lymphoma,
desmoplastic small round cell tumor (DSRCT), and round-cell liposarcoma [20–25].
For almost three decades, the standard immunohistochemical marker for EwS has been the
membranous glycoprotein CD99 [1,26], which shows a striking sensitivity but low specificity for
EwS [27–31]. Since fusions of the FET family of genes comprising FUS, EWSR1, and potentially TAF15,
with members of the ETS family of transcription factors (including FLI1, ERG, ETV1/4/6 and FEV) are
largely pathognomonic for EwS [32–34], molecular identification of such fusions is the most reliable
diagnostic test for EwS to date [24]. The most common fusion genes are EWSR1-FLI1 and EWSR1-ERG,
occurring in around 85% and 10% of cases, respectively.
However, many current standard methods used for molecular diagnosis in pathology are not
infallible. For instance, PCR analyses may fail to detect all FET-ETS variants unless multiplexed PCRs
covering all known variants are employed [35,36]. In addition, fluorescence in situ hybridization
(FISH) approaches, commonly used to detect EWSR1 break-apart, can miss EwS cases with FUS-ETS
fusions [37], are often challenging in EWSR1-ERG-positive EwS [38], or can be misleading in
morphological mimics, such as DSRCT harboring pathognomonic EWSR1-WT1 fusions [24,39,40] or
EWSR1-NFATc2 fusion positive small-round-cell sarcomas [40–42].
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Therefore, a progressively increasing number of institutes nowadays employ more advanced
approaches as auxiliary methods to confirm or rule out the diagnosis of EwS, such as next-generation
sequencing (NGS) to directly sequence the fusion transcripts [43] and/or microarray-based
methylation-profiling [41,44].
However, these sophisticated molecular diagnostic tools are not available at every institution
worldwide and, in some cases, not feasible due to the quantity and/or quality of the available tumor
specimen. Therefore, we strived to identify highly specific auxiliary diagnostic markers that can be
detected by widely available and inexpensive immunohistochemistry (IHC) [27]. Using comparative
transcriptomics in EwS and 20 morphological mimics, we previously identified the proteins BCL11B
(B-cell lymphoma/leukemia 11B) and GLG1 (Golgi apparatus protein 1) as potential auxiliary markers
that can support the diagnosis of EwS [27]. Besides BCL11B and GLG1, out of all 19,702 genes
represented on the employed microarray platform, only ATP1A1 showed significant overexpression
(log2 expression difference >2) in EwS compared to samples of the 20 morphological mimics tested [27].
Hence, BCL11B, GLG1, and ATP1A1 appeared as most promising auxiliary markers for diagnosing
EwS by immunohistochemistry.
BCL11B is a transcription factor mainly involved in T cell development, which was previously
identified as a direct EWSR1-FLI1 target gene contributing to the malignant phenotype of EwS [45].
GLG1 encodes a glycoprotein of still unknown function, even though it was first described in humans
in 1990 [46]. In our discovery study (Baldauf et al. 2018) comprising 47 EwS cases and 127 samples
of morphological mimics on tissue microarrays (TMAs) [27], we found that both proteins are highly
overexpressed in the majority of EwS primary tumors, which is likely due to binding of EWSR1-FLI1
to super-enhancer regions spanning their encoding genes [27]. Although analyses for ATP1A1 showed
the same results, ATP1A1 did neither improve sensitivity nor specificity of the marker combination,
and was not further investigated [27].
In the current study, we aimed at (I) validating the high specificity of BCL11B and GLG1
overexpression for EwS in a new, much larger, and independent cohort, (II) testing the applicability of
these markers also for EWSR1-ERG-positive EwS, and (III) determining the degree of intra-tumoral
marker heterogeneity. To this end, TMAs of 453 cases including 133 EwS cases and 320 cases from 11
differential diagnoses were constructed and stained for BCL11B, GLG1, and CD99. Immunoreactivity
was assessed independently by three researchers based on a modified Remmele and Stegner scoring
system [47].
Our results confirm the high specificity of BCL11B and GLG1 for EwS regardless of the underlying
fusion type, enabled the refinement of cut-off values for classifying cases as ‘positive’ or ‘negative’
for the given marker, and revealed intra-tumoral heterogeneity of the proposed auxiliary markers
to be negligible in differential diagnoses for EwS. These findings lead us to propose a work-flow for
diagnosing EwS on the basis of IHC detection of CD99, BCL11B, and GLG1, which could be widely
applied independent of the availability of molecular pathology diagnostics.
2. Results
2.1. IHC for CD99 and FISH for EWSR1 Break-Apart Are Not Fully Sufficient to Diagnose EwS
The histological small-round-cell phenotype is shared by several cancer entities including EwS.
Therefore, if such histology is present and EwS is suspected, fluorescence in situ hybridization (FISH)
for detection of EWSR1 break-apart and immunohistochemical CD99 stains are commonly performed
in pathological routine diagnostics for exclusion or diagnosis of EwS [1]. Yet, EWSR1 break-apart occurs
in several morphological mimics of EwS such as DSRCT harboring a pathognomonic EWSR1-WT1
fusion, and angiomatoid fibrous histiocytoma (AFH) commonly positive for EWSR1-ATF1 fusions
(Figure 1).
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Figure 1. Immunohistochemistry (IHC) for CD99 and fluorescence in situ hybridization (FISH) for
EWSR1 break-apart are not sufficient to constitute the diagnosis EwS. From left to right: representative
micrographs of Ewing sarcoma (EwS) positive for EWSR1-FLI1 or EWSR1-ERG, desmoplastic small
round cell tumor (DSRCT) positive for EWSR1-WT1, and an angiomatoid fibrous histiocytoma (AFH)
positive for EWSR1-ATF1, stained with H&E, or for CD99, BCL11B, and GLG1. The scale bar applies
to all micrographs and indicates 40 µm, insets for GLG1 are enlarged by factor two. In all cases, an
EWSR1 break-apart was detected by FISH.
CD99 is the standard IHC marker in pathological workup of potential EwS samples [26]. However,
to the best of our knowledge, no international guidelines were established on how to standardize the
scoring and interpretation of CD99 immunoreactivity in EwS. In addition, CD99 is highly expressed in
several other cancer types [48–50], and its specificity for EwS among differential diagnoses was found
to be remarkably low in our previous study (17% at a cut-off of 2 [27]).
To further assess the sensitivity and specificity of CD99 immunoreactivity for EwS, we
systematically scored CD99 immunoreactivity using our modified Remmele and Stegner scoring
system in a series of n = 133 molecularly confirmed EwS tumors and n = 320 morphological mimics
from 11 differential diagnoses (Table 1).
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Table 1. Composition of the tissue microarrays (TMAs). EwS, Ewing sarcoma; DSRCT, desmoplastic
small round cell tumor; GIST, gastrointestinal stromal tumor; dediff, dedifferentiated.
Tumor Entity n
EwS 133
Chondrosarcoma 23
DSRCT 7
GIST 13
Hepatoblastoma 23
Leiomyosarcoma 45
Liposarcoma (dediff./myxoid) 26 (17/9)
Nephroblastoma 33
Neuroblastoma 92
Osteosarcoma 29
Rhabdomyosarcoma 19
Synovial sarcoma 10
total 453
In this cohort, CD99 showed high sensitivity for EwS ranging from 100% at an immunoreactive
score (IRS) cut-off of >0 to 88% for an IRS cut-off of >9 (Table 2). However, the specificity of CD99
immunoreactivity proved to be rather low ranging from 2.5% to 67.5% depending on the chosen cut-off
(Table 2). Even the highest CD99 IRS score of 12 was observed in some instances of morphological
mimics of EwS, such as DSRCT (Figure 1). Accordingly, the high sensitivity of CD99 for EwS even
at high IRS cut-offs may indicate that only strongly CD99 positive samples should be considered as
potential EwS, and that samples only faintly stained for CD99 should be rather regarded as “negative”.
Table 2. Sensitivity and specificity of CD99 immunoreactivity in EwS. IRS, immunoreactive score.
Cut-Off
(CD99 IRS > Indicated Value) Sensitivity (%) Specificity (%)
0 100.0 2.5
1 100.0 6.6
2 100.0 10.0
3 99.2 18.1
4 98.5 26.9
6 95.5 43.8
8 91.0 60.0
9 88.0 67.5
Collectively, the representative cases shown in Figure 1 and our systematic scoring of CD99
demonstrate that the detection of an EWSR1 break-apart in FISH in conjunction with immunoreactivity
for CD99 are not fully sufficient to robustly diagnose EwS, suggesting that more sophisticated
molecular pathology techniques, such as qRT-PCR, RNA-sequencing [51,52] or comparative methylation
profiling [41,44], should be employed. Alternatively, highly specific auxiliary immunohistochemical
markers could be used in conjunction with CD99 to compensate for its lack of specificity. In our
prior discovery study, we proposed, based on comparative transcriptomics and preliminary
immunohistochemical validation, BCL11B and GLG1 as potentially useful auxiliary markers for
immunohistochemical diagnosis of EwS [27]. Indeed, the high and distinct nuclear (BCL11B) or
perinuclear (GLG1) expression of both markers was very helpful to establish the diagnosis of EwS in the
two representative EwS cases shown in Figure 1, which were molecularly verified by next-generation
sequencing (NGS; Archer FusionPlex Sarcoma panel).
Cancers 2020, 12, 644 6 of 17
2.2. High Immunoreactivity for BCL11B and/or GLG1 Is Specific for EwS
To assess the diagnostic value of the proposed auxiliary markers BCL11B and GLG1, all 453
cases of our new cohort (Table 1), were semi-quantitatively scored for their immunoreactivity using a
modified Remmele and Stegner [47] scoring system (see Methods).
We observed that BCL11B and GLG1 were highly expressed in EwS. In fact, 75.9% of EwS cases
(101/133) were highly reactive for at least one marker, co-expression of both was detected in 32.3% of
EwS cases (43/133) (Figure 2a,b); 48.9% of cases (65/133) exhibited high immunoreactivity for BCL11B
and 59.4% (79/133) for GLG1. High immunoreactivity was set as 60% of EwS cells per sample stained
with at least intermediate intensity (IRS ≥6).
Figure 2. High immunoreactivity for BCL11B and GLG1 is diagnostic for EwS in CD99 positive samples.
(a) Venn diagram representing all EwS samples in the TMA cohort of this study, the BCL11B and GLG1
high-expressing samples (at least 60% tumor cells stained, at least intermediate intensity) and their
overlap. (b) Dot-plots indicating IRS values for CD99, BCL11B, and GLG1 in EwS and 11 differential
diagnoses. The number of samples per entity is given in brackets. Bars indicate mean IRS; dashed lines
indicate optimal cut-offs.
As CD99 proved to be highly sensitive for EwS in our cohort, we considered only those samples
as potential EwS with a CD99 IRS of at least 2 (100% sensitivity for EwS; Figure 2b). To define the
diagnostically most informative combination of BCL11B and GLG1 immunoreactivity for EwS (only
one marker positive/ at least one positive/ both positive; each marker with all different mathematically
possible IRS cut-offs), we performed automated sensitivity and specificity calculations. To this end, we
focused on combinations with the highest specificity for EwS, because lack of specificity is a major
issue of routinely applied diagnostic tools in EwS.
After filtering out all marker combinations with a specificity for EwS <95%, we selected the
marker combination with the highest sensitivity. Through this process, we noted the positivity of at
least one marker with IRS cut-offs >6 and >9 for BCL11B and GLG1, respectively, to be highly specific
(95.6%) but moderately sensitive (64.7%) for EwS (Figure 2b). Interestingly, CD99 with an IRS cut-off
>2 did not raise the specificity of this marker combination. Only at an IRS cut-off >8 for CD99, the
specificity for immunohistochemical diagnosis of EwS could be slightly increased to 97.5%, while the
sensitivity slightly dropped to 63.2%.
To test, whether this marker specificity is not limited to the most common fusion type in EwS
(EWSR1-FLI1), open slides of six molecularly confirmed EWSR1-ERG-positive EwS cases were stained
for BCL11B and GLG1. Strikingly, BCL11B exhibited in all cases the highest possible IRS of 12 (for
example see Figure 1), while the IRS for GLG1 ranged from 0–8.
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We previously showed that BCL11B and GLG1 mRNA expression is upregulated by EWSR1-FLI1
in EwS cell lines harboring this specific fusion type [27]. To test whether the marker transcripts
can be upregulated also by EWSR1-ERG, we assessed their expression by qRT-PCR in three
EWSR1-ERG-positive EwS cell lines with/without RNA interference-mediated EWSR1-ERG silencing.
As shown in Supplementary Figure S1a, knockdown of EWSR1-ERG was accompanied by
downregulation of BCL11B and GLG1 expression in all three cell lines tested, suggesting that these
markers are also upregulated by EWSR1-ERG in EwS harboring this fusion (around 10% of cases).
In conjunction with the scoring results of the six molecularly confirmed EWSR1-ERG-positive EwS
cases, these experimental results further suggest that high expression of both marker proteins in
primary EwS is not restricted to EWSR1-FLI1-positive tumors.
Since patient-derived xenografts (PDX) are increasingly used as preclinical models to study EwS
biology [48], we tested the expression pattern of BCL11B and GLG1 in PDX from EwS and non-EwS
patients (18 PDX models originating from 15 EwS patients; 52 PDX models originating from 49 non-EwS
patients). As expected, expression of both markers was higher for PDX from EwS patients as compared
to the non-EwS PDX (Supplementary Figure S1b). Interestingly, the tested series of PDX models
included five samples from so-called ‘Ewing-like’ sarcomas (3 CIC-DUX4-positive sarcomas and 2
BCOR-rearranged sarcomas), which did not exhibit any BCL11B and GLG1 immunoreactivity. These
findings in PDX models further support the high specificity of BCL11B and GLG1 for EwS.
2.3. BCL11B and GLG1 Exhibit Low Intra-Tumoral Heterogeneity in Differential Diagnoses for EwS
Tumor material is often limited in pathological workup (e.g., in needle/punch biopsies). In the
context of histological tumor evaluation, limited material can lead to substantial confusion in case of
high intra-tumoral heterogeneity of morphology and diagnostic marker expression. Therefore, the
heterogeneity of scoring for CD99, BCL11B, and GLG1 in different cores per sample, originating from
different regions of a given tumor block, was assessed. For non-EwS, 248 samples with three cores per
marker were available in our TMA-cohort. Samples were classified as high or low for the different
markers applying the thresholds defined above (Figure 2b).
For CD99, 81% of non-EwS tumor samples were classified consistently across all three cores per
sample, for BCL11B 97.6%, and for GLG1 and 94.8% (Figure 3), indicating only little intra-tumoral
heterogeneity in EwS differential diagnoses. When combining the three markers, in 95.2% of all non-EwS
samples all three cores were classified consistently as EwS or non-EwS. Hence, even when only little
material of non-EwS cases is available, misclassification as EwS because of marker heterogeneity
is highly unlikely, and the specificity of the markers is not affected. The observed intra-tumoral
heterogeneity in differential diagnosis for EwS can therefore be regarded as rather negligible.
Figure 3. BCL11B and GLG1 show low intra-tumoral expression heterogeneity in differential diagnosis
for EwS. Pie charts indicating non-EwS samples with three cores evaluated in each staining (n = 248) that
were classified as high- or low-expressing the respective marker consistently (grey) or inconsistently
(light red) across all three cores.
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In our TMA-cohort, most EwS samples were represented by two cores. For n = 96 EwS cases
two cores were present in each staining. In these 96 EwS cases, we found consistent classification as
marker-positive or -negative in 81.1%–87.4% (Supplementary Figure S2).
In sum, these results suggest that the combination of CD99 as a screening marker and the highly
specific auxiliary markers BCL11B and GLG1 may be applicable even in cases where only scarce
material is available.
2.4. Proposed Work-Flow for Immunohistochemical Assessment of EwS
Given the above-mentioned results and in support of the findings of Baldauf et al. 2018 [27], we
propose the following work-flow for immunohistochemical assessment of EwS: First, CD99 staining
should be performed. If the IRS is equal or lower than 8, the suspected diagnosis should be reconsidered.
In cases with a CD99 IRS greater than 8 (meaning strong membranous staining intensity in at least 60%
of tumor cells), the diagnosis of EwS should be either confirmed by molecular pathology approaches
that can reliably detect FET-ETS fusions such as qRT-PCR or RNA-seq, or by immunohistochemical
staining for the auxiliary markers BCL11B and GLG1.
The diagnosis of EwS can be confidently established in case of high BCL11B immunoreactivity
(IRS >6; i.e., moderate nuclear staining intensity in at least 80% of tumor cells, or strong nuclear
staining intensity in at least 60% of tumor cells) and/or high GLG1 immunoreactivity (IRS >9; i.e.,
strong perinuclear staining in at least 80% of tumor cells). If both markers show immunoreactivity
scores below the respective cut-off, the diagnosis of EwS should be molecularly confirmed (Figure 4a).
Applying this algorithm to our cohort of 133 EwS cases and 320 cases from differential diagnoses yields
a positive predictive value of 91.3% and a negative predictive value of 86.4% (Figure 4b)
Figure 4. Cont.
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Figure 4. Proposed work-flow for immunohistochemical diagnosis of EwS. (a) Scheme of the proposed
work-flow for immunohistochemical diagnosis of EwS; (b) pie charts indicating the performance of the
proposed diagnostic procedure in the cohort of 133 EwS and 320 samples of 11 differential diagnoses.
3. Discussion
Robust diagnostics are essential to quickly and correctly assign EwS patients to the appropriate
therapy. After initial clinical presentation and imaging, the diagnostic workup of potential EwS patients
is performed by surgical pathologists. As EwS belongs to the group of undifferentiated small-round-cell
sarcomas [19], its histological phenotype is shared by several differential diagnoses [53].
In histopathological examination, evaluation of H&E-stained slides is routinely followed by
CD99 immunostaining [26], which is commonly positive in the vast majority of EwS cases [26,54].
In accordance, the CD99 IRS for 91% (121/133) of EwS in our TMA cohort was >8.
However, even strong membranous CD99 immunoreactivity is not specific for EwS [28,55]. Indeed,
40% of non-EwS cases examined in the current study (128/320 samples, representing 11 distinct tumor
entities) exhibited a strong CD99 immunostaining (IRS >8). Accordingly, in most institutions, the
diagnosis of EwS is further validated by molecular pathology techniques, most commonly FISH to
detect break-apart events in the EWSR1 gene [24]. Although a positive result is highly sensitive for
EwS, some morphological mimics can exhibit break-apart events in the EWSR1 gene (e.g., DSRCT,
AFH, and EWSR1-NFATc2-positive sarcomas) [39–41].
Another molecular technique is multiplex qRT-PCR to amplify pathognomonic FET-ETS fusion
transcripts. However, due to the large variety of existing FET-ETS fusions in EwS [56], many of the
currently used multiplex PCR sets likely do not cover all possible FET-ETS fusions. As a consequence,
many institutions increasingly employ next-generation RNA-sequencing technologies to overcome
these limitations. Yet, these techniques are not available or feasible in all cases, which is why a
straight-forward immunohistochemical approach is still desirable.
Hence, many groups have evaluated several potential diagnostic markers such as FLI1, NKX2-2,
and PAX7 that could be used instead of the highly unspecific marker CD99 [40,57,58]. However, to
the best of our knowledge, none of these proposed IHC markers completely fulfills the requirements
of providing very high sensitivity and specificity for EwS at the same time. While FLI1 is unable to
confirm EwS cases with FET–non-FLI1 translocations [33,59], NKX2-2 and PAX7 lack specificity [60]
and can be even strongly expressed in close morphological mimics such as EWSR1-NFATc2-positive
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sarcomas [40,57,58]. Besides, also Caveolin-1 [54,61], Cyclin-D1 [62], and NR0B1 [63] have been
proposed as potential (auxiliary) IHC markers for EwS. While Cyclin-D1 and NR0B1 showed high
sensitivity for EwS, they were reported as being not fully specific, which is why it was proposed to use
them in an IHC marker panel [62,64]. Caveolin-1 is another highly sensitive IHC marker for EwS [54]
but its specificity has—to the best of our knowledge—not been systematically assessed yet. The fact
that Caveolin-1, Cyclin-D1, NKX2-2, NR0B1 and PAX7 are known FET-ETS target genes [57,61,63,65,66]
implies that not every FET-ETS target gene may serve as a highly specific auxiliary marker, since they
may be also expressed at high levels in some morphological mimics.
To this end, we set out to identify highly specific auxiliary markers that can compensate the lack
of specificity of CD99. By comparative transcriptome profiling of EwS cases and hundreds of samples
from 20 morphological mimics, we previously identified three highly specific marker candidates,
namely ATP1A1, BCL11B, and GLG1 [27]. Using IHC in a series of 47 EwS and 127 non-EwS tumors
from 11 distinct entities, we found that high BCL11B and/or high GLG1 expression in CD99-positive
cases may be diagnostic for EwS, while ATP1A1 did neither raise the specificity nor sensitivity of this
marker combination further [27]. However, even broader transcriptome analyses covering more than
the investigated 19,702 genes and/or comparative proteomics analyses could yield additional auxiliary
markers that are currently unknown.
In the current study, we confirmed the high specificity of BCL11B and GLG1 for EwS in a far larger
and independent cohort of 133 EwS and 320 non-EwS from 11 differential diagnoses, including 118
samples from close morphological mimics such as DSRCT, neuroblastoma, and rhabdomyosarcoma.
This high number of samples enabled a refinement of the IRS cut-offs for both markers (BCL11B
>6, GLG1 >9; compared to previously proposed cut-offs >9 for both markers). In conjunction with
the highly sensitive marker CD99, our approach yielded a specificity of 97.5% and an accuracy of
87.4% for diagnosing EwS solely by IHC. Also, EwS cases with EWSR1-ERG fusions exhibited high
marker immunoreactivity.
However, it should be noted that in our cohort, 36.8% of EwS cases could not be confirmed
by this marker combination. If, in these cases, there is strong clinical suspicion of EwS, additional
molecular approaches are mandatory for diagnosis. Additionally, in the current study, we used specific
polyclonal antibodies against BCL11B and GLG1 (see methods). To further improve the accuracy of our
diagnostic IHC approach and to reduce the risk of batch effects across different polyclonal antibodies,
we recommend to systematically develop and improve monoclonal antibodies against both antigens
that can be employed for IHC.
As tumor material is often limited, heterogeneously expressed markers can lead to misdiagnoses
depending on the tumor fraction captured in a given sample. Hence, homogeneous expression of
potential markers within tumors is desirable. For non-EwS cases, the proposed marker combination of
CD99, BCL11B, and GLG1 yielded a consistent classification over all 3 cores taken from different areas
of each tumor sample in 95.2%. These findings suggest that the specificity of our approach is likely not
compromised even when only little tumor material is available for diagnostics. Marker homogeneity
in EwS was only moderate, possibly explaining the observed moderate sensitivity of our markers in
our TMA cohort (representing each EwS sample with two 1 mm cores, in other words 1.6 mm2 tumor
material). Potentially, the sensitivity might be even higher when more tumor material is available.
It should be noted that both auxiliary markers need to be carefully scored according to a modified
Remmele and Stegner IRS. That is, both markers do not exhibit an ‘all-or-nothing’ expression pattern
and rather display substantial expression variability in EwS and non-EwS cases. Thus, the actual
immunoreactivity needs to be compared to visual analogous scales (see Baldauf et al. 2018 [27]),
especially by pathologists with little experience with these markers. Yet, since most non-EwS cases do
not exhibit any or only very weak positivity for both markers, and EwS exhibit very strong positivity,
we believe that our auxiliary markers could easily be implemented on routine IHC workup of suspected
EwS cases.
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4. Materials and Methods
4.1. Human Samples and Ethics Approval
The study was conducted in accordance with the Declaration of Helsinki. Formalin-fixed
paraffin-embedded (FFPE) human tissue samples of EwS and differential diagnoses were retrieved from
the archives of the Institute of Pathology of the LMU Munich (years 2009 to 2019) and collaborating
institutions with approval of the ethics committee of the LMU Munich University Hospital (307-16
UE). Patient derived xenografts (PDX) were provided by the Childhood Solid Tumor Network [67],
D. Surdez and O. Delattre (Paris, France), and A. Henssen (Berlin, Germany) with approval of the
corresponding institutional review boards.
4.2. Construction of Tissue Microarrays (TMA) and Immunohistochemistry (IHC)
A total of 348 FFPE primary tissue samples and FFPE PDX samples from 64 pediatric sarcomas
were collected. Only samples that could be diagnosed unambiguously using current state-of-the-art
diagnostics for the respective tumor entity, were further processed. For each tumor, all FFPE blocks
were examined in H&E stained slides and the tumor block containing the largest amount of vital tumor
tissue was selected for TMA construction (three cores per tumor block, each with a diameter of 1 mm,
and internal controls). Additionally, TMAs with 144 EwS samples and at least two cores per sample
were obtained from W. Hartmann and U. Dirksen (Münster and Essen, Germany). The composition of
the final cohort comprising n = 453 samples is given in Table 1.
For IHC, newly cut 4 µm sections of TMAs or available open slides for n = 6 EWSR1-ERG positive
EwS samples, n = 1 EWSR1-ATF1 positive angiomatoid fibrous histiocytoma (AFH), and n = 12 PDX
models were used. Antigen retrieval was performed with microwave treatment, 2 × 15 min at 750 W
using the antigen retrieval AR-10 solution (HK057-5K, DCS Innovative, Hamburg, Germany) for
GLG1 and the Dako Target Retrieval Solution (S1699, Agilent, Santa Clara, CA, USA) for BCL11B.
After rinsing the slides with pH 7.5 TRIS buffer (0.05 M; Sigma, Taufkirchen, Germany), endogenous
peroxidase was blocked by 7.5% aqueous H2O2 solution at room temperature and blocking serum
from the corresponding kits for 20 min.
Slides were then incubated for 60 min with primary rabbit-anti-human antibodies anti-BCL11B
(1:1000 dilution; ab70453, Abcam, Cambridge, UK), or anti-GLG1 (1:250 dilution; HPA010815, Atlas
Antibodies, Bromma, Sweden). Then slides were incubated with a secondary anti-rabbit IgG antibody
(ImmPress Reagent Kit, peroxidase-conjugated) followed by target detection using AEC plus chromogen
for 10 min (K3461, Agilent).
For IHC staining of CD99, 4 µm sections were incubated for 32 min with a monoclonal
mouse-anti-human antibody (1:40 dilution; 12E7, Agilent) using the ultraView detection kit in a
VENTANA BenchMark system (Roche, Basel, Switzerland).
4.3. Evaluation of Immunoreactivity and Automated Cut-Off Finding
Immunoreactivity of all TMAs and open slides for CD99, BCL11B, and GLG1 was semi-
quantitatively scored by three independent physician-scientists in analogy to scoring of hormone
receptors with the immunoreactive score (IRS) established by Remmele and Stegner [47] with slight
modifications of the grading of the percentage of positive tumor cells. First, the percentage of stained
tumor cells was determined as the average of at least three high-power fields (40×) and rated on a
scale of 0–4 (grade 0 = 0%–19%, grade 1 = 20%–39%, grade 2 = 40%–59%, grade 3 = 60%–79%, and
grade 4 = 80%–100%). Second, for samples with marker immunoreactivity, the most representative
intensity was determined (grade 1 = low, grade 2 = moderate, and grade 3 = strong staining intensity).
The product of these two grades defined the final IRS. After filtering out samples without representative
tumor material on TMAs, the few samples with high inter-observer scoring deviation were revised and
a consensus was built. High inter-observer scoring deviation was assumed if the sum of the absolute
differences between the score of each observer and the mean IRS was at least as high as the mean
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IRS. Automated cut-off finding and combination testing were performed with an in-house VBA script
implemented in Microsoft Excel (2016, 32-bit) as described in our discovery study [27].
4.4. Evaluation of Heterogeneity of Intra-Tumoral Marker Expression
To test whether the markers investigated in this study were heterogeneously expressed in a given
differential diagnosis for EwS, we selected all tumor samples for which representative material was
present in all three cores of the respective TMA for CD99, BCL11B, and GLG1 staining. In a next
step, we evaluated for each core whether the IRS values for CD99, BCL11B, and GLG1 exceeded the
predefined cut-offs (>8, >6, >9, respectively, see Results section) to classify each core as either marker
high/positive or low/negative. Then, we assessed whether the results were consistent across all three
cores per tumor sample. As most EwS cases were represented by two cores per sample, the evaluation
of marker expression heterogeneity for EwS was performed separately on samples with two cores
present in each staining.
4.5. RNA Extraction, Reverse Transcription, and Quantitative Real-Time PCR (qRT-PCR)
To test for potential transcriptional regulation of BCL11B and GLG1 by EWSR1-ERG, we employed
clones of three EWSR1-ERG positive EwS cell lines (CHLA25, EW3, and TC106) harboring a doxycycline
inducible shRNA mediated EWSR1-ERG knockdown system. Wild-type CHLA25 and TC106 cells
were obtained from the Children’s Oncology Group (COG), and EW3 cells were kindly provided by
O. Delattre. Cell line authenticity was confirmed by STR-profiling and mycoplasma contamination
was ruled out by nested PCR. Total RNA was extracted from these EwS cell lines 96 h after induction
of EWSR1-ERG knockdown using the NucleoSpin RNA kit (Macherey-Nagel, Düren, Germany).
RNA was reversely transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). qRT-PCRs were performed with 1:10 diluted cDNA and 0.5 µM
forward and reverse primers in SYBR Green PCR Master Mix (Applied Biosystems). Oligonucleotides
were purchased from MWG Eurofins Genomics (Ebersberg, Germany). The following primer sequences
were used:
BCL11B forward: 5′-ATGCCAGAATAGATGCCGG-3′;
BCL11B reverse: 5′-CTCTATCTCCAGACCCTCGTC-3′;
GLG1 forward: 5′-GTGGAGTGTAGAGATATAGTTGGC-3′;
GLG1 reverse: 5′-ATCAGGTCCCCAGAGTCTATC-3′;
RPLP0 forward: 5′-GAAACTCTGCATTCTCGCTTC-3′;
RPLP0 reverse: 5′-GGTGTAATCCGTCTCCACAG-3′.
Reactions were run on a BioRad CFX Connect instrument (Bio-Rad, Munich, Germany) with the
following thermal conditions: heat activation (95 ◦C, 2 min), DNA denaturation (95 ◦C, 10 s), annealing
and elongation (60 ◦C, 30 s), 49 repeat cycles, final denaturation (95◦C, 30 s). RPLP0 was used as
housekeeping gene [68].
5. Conclusions
We anticipate that the here proposed diagnostic procedure (Figure 4a) will provide robust diagnosis
in a large fraction of EwS cases even without any additional molecular diagnostic techniques, which
may be of great benefit for patients, especially in settings in which molecular diagnostic approaches
are not available or feasible.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/3/644/s1,
Figure S1: EWSR-ERG knockdown leads to decrease of BCL11B and GLG1 expression in EwS cell line models
and PDX EwS models exhibit high immunoreactivity for BCL11B and GLG1; Figure S2: BCL11B and GLG1 show
moderate intra-tumoral staining heterogeneity in EwS.
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